The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Coloma R.N.

School of Medicine, Antenor Orrego Private University

Niler S.P.

School of Medicine, Antenor Orrego Private University

Gustavo F.T.

School of Medicine, Antenor Orrego Private University

Chávez-Velásquez A.L.

School of Medicine, Antenor Orrego Private University

Zavaleta-Corvera C.

School of Medicine, Antenor Orrego Private University

Impact of tumor size on actuarial survival of patients with primary breast sarcoma: a case-control study

Authors:

Coloma R.N., Niler S.P., Gustavo F.T., Chávez-Velásquez A.L., Zavaleta-Corvera C.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2024;(12): 38‑43

DOI: 10.17116/hirurgia202412138

Read: 1317 times

Download PDF (RU)
Contact the author
Table of contents

IMPACT OF TUMOR SIZE ON ACTUARIAL SURVIVAL OF PATIENTS WITH PRIMARY BREAST SARCOMA: A CASE-CONTROL STUDY
IMPACT OF TUMOR SIZE ON ACTUARIAL SURVIVAL OF PATIENTS WITH PRIMARY BREAST SARCOMA: A CASE-CONTROL STUDY

To cite this article:

Coloma RN, Niler SP, Gustavo FT, Chávez-Velásquez AL, Zavaleta-Corvera C. Impact of tumor size on actuarial survival of patients with primary breast sarcoma: a case-control study. Pirogov Russian Journal of Surgery. 2024;(12):38‑43. (In Russ.)
https://doi.org/10.17116/hirurgia202412138

Подписка 2026 Хирургия. Журнал им. Н.И. Пирогова (Pirogov Russian Journal of Surgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Repeated breast reco­nstruction after previous complications. Piro­gov Russian Journal of Surgery. 2025;(6):51-57
Left ventricular myocardial performance index (Tei index) as an early marker of cardiotoxicity in anti­tumor therapy. Russian Cardiology Bulletin. 2024;(4-2):137-143
Nottingham Prognostic Index rela­tion to cyto­kine-producing tumor mole­cular subtypes in breast cancer. Russian Journal of Preventive Medi­cine. 2025;(1):63-68
Asse­ssment of the quality of life of patients after dental surgeries using kine­siotaping and infrared laser therapy. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6-2):110-116
The possibilities of predicting and redu­cing the risk of breast cancer in women against the background of the use of assi­sted reproductive technologies. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):59-64
Neoadjuvant drug therapy and onco­logical outcomes in patients with stage I–II breast cancer. P.A. Herzen Journal of Onco­logy. 2025;(1):5-12
The effect of acetylamide synthetic peptide HLDF-6 on cell differentiation in breast cancer. Russian Journal of Archive of Pathology. 2025;(2):5-10
Treatment outcomes of stage IIA–IIB breast cancer patients of hormone-positive HER2-negative subtype after neoadjuvant poly­chemotherapy depe­nding on Ki-67 levels. P.A. Herzen Journal of Onco­logy. 2025;(2):13-18
Radi­cal cystectomy with fertility preservation for non-muscle inva­sive bladder cancer. P.A. Herzen Journal of Onco­logy. 2025;(2):76-82
Ergo­spirometry for preoperative risk asse­ssment in patients with colo­rectal cancer. Russian Journal of Anesthesiology and Reanimatology. 2025;(3):70-77
Abstract:

OBJECTIVE. T

O determine whether tumor size, categorized as >5 cm or ≤5 cm, influences overall survival in patients with primary breast sarcoma.

MATERIAL AND METHODS

The study population consisted of patients diagnosed with primary breast sarcoma between January 1, 2010, and December 31, 2020. Patients with histologically confirmed primary breast sarcoma were included and divided into two groups according to tumor size: cases (>5 cm) and controls (≤5 cm). Survival was evaluated throughout the follow-up period ranging from 2 years and 6 months to 3 years and 6 months.

RESULTS

Of 2173 breast cancer cases registered during the study period, 20 patients met the inclusion criteria for primary breast sarcoma. Of these, 13 ones had tumors >5 cm, while 7 ones had tumors ≤5 cm. Mean age of patients was 48 years, 70% of patients were older 40 years. Tumors larger than 5 cm represented 65% of cases. However, no significant difference in overall survival was observed between both groups (p=0.37).

CONCLUSION

Although a difference in median survival was found between patients with tumors larger and smaller than 5 cm, multivariate analysis did not demonstrate tumors > 5 cm as a significant prognostic factor for decreased survival.

Keywords:

Breast Cancer
Primary Sarcoma
Tumor Size
Survival
Multivariate Analysis
Surgical Intervention
Histology

Authors:

Coloma R.N.

School of Medicine, Antenor Orrego Private University

Niler S.P.

School of Medicine, Antenor Orrego Private University

Gustavo F.T.

School of Medicine, Antenor Orrego Private University

Chávez-Velásquez A.L.

School of Medicine, Antenor Orrego Private University

Zavaleta-Corvera C.

School of Medicine, Antenor Orrego Private University

Received:

04.03.2024

Accepted:

13.04.2024

Close metadata

References:

  1. Kashyap D, Pal D, Sharma R, Garg VK, Goel N, Koundal D, et al. Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures. Biomed Res Int. 2022;2022:9605439. Epub 2022/04/29.. PubMed PMID: 35480139; PubMed Central PMCID: PMCPMC9038417. https://doi.org/10.1155/2022/9605439
  2. Torres-Roman JS, Martinez-Herrera JF, Carioli G, Ybaseta-Medina J, Valcarcel B, Pinto JA, et al. Breast cancer mortality trends in Peruvian women. BMC Cancer. 2020;20(1):1173. https://doi.org/10.1186/s12885-020-07671-x
  3. Kumar S, Sharma J, Ralli M, Singh G, Kalyan S, Sen R. Primary Stromal Sarcoma of Breast: A Rare Entity. Iran J Pathol. 2016;11(5):469-73. Epub 2017/10/05. PubMed PMID: 28974969; PubMed Central PMCID: PMCPMC5604113.
  4. Morales-Miranda A, Robles-Vidal L, Bargallo E. Primary Breast Sarcoma: A rare pathology in women from the National Cancer Institute (INCan) of Mexico. Cancer Reports and Reviews. 2018;2.  https://doi.org/10.15761/CRR.1000147
  5. Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020;368(6494):973-80. Epub 2020/05/30.. PubMed PMID: 32467386; PubMed Central PMCID: PMCPMC7757858. https://doi.org/10.1126/science.aay9189
  6. Gomez-Brouchet A, Illac C, Gilhodes J, Bouvier C, Aubert S, Guinebretiere JM, et al. CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial. Oncoimmunology. 2017;6(9):e1331193. Epub 2017/09/22.. PubMed PMID: 28932633; PubMed Central PMCID: PMCPMC5599091. https://doi.org/10.1080/2162402x.2017.1331193
  7. Grünewald TG, Alonso M, Avnet S, Banito A, Burdach S, Cidre-Aranaz F, et al. Sarcoma treatment in the era of molecular medicine. EMBO Mol Med. 2020;12(11):e11131. Epub 2020/10/14.. PubMed PMID: 33047515; PubMed Central PMCID: PMCPMC7645378. https://doi.org/10.15252/emmm.201911131
  8. Wang J, Wang WL, Sun H, Huo L, Wu Y, Chen H, et al. Expression of TRPS1 in phyllodes tumor and sarcoma of the breast. Hum Pathol. 2022;121:73-80. Epub 2022/01/23.. PubMed PMID: 35063444. https://doi.org/10.1016/j.humpath.2022.01.002
  9. Lee JS, Yoon K, Onyshchenko M. Sarcoma of the Breast: Clinical Characteristics and Outcomes of 991 Patients from the National Cancer Database. Sarcoma. 2021;2021:8828158. https://doi.org/10.1155/2021/8828158
  10. Hsu C, McCloskey SA, Peddi PF. Management of Breast Sarcoma. Surgical Clinics of North America. 2016;96(5):1047-58.  https://doi.org/10.1016/j.suc.2016.05.004
  11. Gutnik L, Ren Y, Thomas SM, Plichta JK, Greenup RA, Fayanju OM, et al. Malignant phyllodes tumor and primary breast sarcoma; distinct rare tumors of the breast. J Surg Oncol. 2022;125(6):947-57. Epub 2022/02/19.. PubMed PMID: 35179788; PubMed Central PMCID: PMCPMC8995353. https://doi.org/10.1002/jso.26820
  12. Yin M, Mackley HB, Drabick JJ, Harvey HA. Primary female breast sarcoma: clinicopathological features, treatment and prognosis. Sci Rep. 2016;6:31497. Epub 2016/08/12.. PubMed PMID: 27510467; PubMed Central PMCID: PMCPMC4980597 Genentech. The other authors declare no conflict of interest. https://doi.org/10.1038/srep31497
  13. Matsumoto R, Hsieh SJK, Chala LF, de Mello GGN, de Barros N. Sarcomas of the breast: findings on mammography, ultrasound, and magnetic resonance imaging. Radiol Bras. 2018;51(6):401-6. Epub 2018/12/19.. PubMed PMID: 30559558; PubMed Central PMCID: PMCPMC6290740. https://doi.org/10.1590/0100-3984.2016.0141
  14. González Ortega JM, Morales Wong MM, Gómez Hernández MM, López Cuevas ZC, Escaig Olivares RL, González Folch R. Tumores mesenquimales de la mama. Revista Médica Electrónica. 2014;30(2):11. Epub 2014-03-03. 
  15. Torres-Aja L, Puerto-Lorenzo JA. Sarcoma primitivo de mama: presentación de un caso. Revista Archivo Médico de Camagüey. 2019;23:797-801. 
  16. El Amine Elhadj O, Nasri M, Thabet S, Ben Hassouna J, Goucha A, Rahal K, et al. [Primary breast sarcomas: About 30 cases treated at Salah-Azaiez institute in Tunisia]. Cancer Radiother. 2017;21(1):45-50. Epub 2017/02/23.. PubMed PMID: 28223032. https://doi.org/10.1016/j.canrad.2016.09.011
  17. Wu HY, Liu L, Gu L, Luo YH. Clinical characteristics and management of primary granulocytic sarcoma of the breast: A case report. Medicine (Baltimore). 2019;98(35):e16648. Epub 2019/08/30.. PubMed PMID: 31464900; PubMed Central PMCID: PMCPMC6736367. https://doi.org/10.1097/md.0000000000016648
  18. Meng T, Zhou Y, Ye MN, Wei JJ, Zhao QF, Zhang XY. Primary highly differentiated breast angiosarcoma in an adolescent girl. Eur Rev Med Pharmacol Sci. 2022;26(4):1299-303. Epub 2022/03/08.. PubMed PMID: 35253186. https://doi.org/10.26355/eurrev_202202_28123
  19. Li S, Xue Q, Shi W. Primary Osteosarcoma of the Breast: A Rare Case Report and Literature Review. Front Oncol. 2022;12:875793. Epub 2022/06/28.. PubMed PMID: 35756647; PubMed Central PMCID: PMCPMC9218342. https://doi.org/10.3389/fonc.2022.875793
  20. Kim YJ, Ryu JM, Lee SK, Chae BJ, Kim SW, Nam SJ, et al. Primary Angiosarcoma of the Breast: A Single-Center Retrospective Study in Korea. Curr Oncol. 2022;29(5):3272-81. Epub 2022/05/28.. PubMed PMID: 35621657; PubMed Central PMCID: PMCPMC9139487. https://doi.org/10.3390/curroncol29050267
  21. Osman MH, Rabie NA, Elmehrath AO, Bedair HM, Fala SY, Ghaith HS, et al. Primary and Secondary Breast Sarcoma: Clinical and Pathological Characteristics, Prognostic Factors, and Nomograms for Predicting Survival. Clin Breast Cancer. 2022;22(7):e753-e63. Epub 2022/08/14.. PubMed PMID: 35963779. https://doi.org/10.1016/j.clbc.2022.07.006
  22. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022;66:15-23. Epub 2022/09/10. PubMed PMID: 36084384; PubMed Central PMCID: PMCPMC9465273. https://doi.org/10.1016/j.breast.2022.08.010
  23. Yache E. Reporte Hospitalario del Cancer 2007 al 2018. Trujillo. Peru: Instituto Regional de Enfermedades Neoplasicas del Norte, 2019.
  24. Cheng Y, Zhang P, Huang Y, Tang R, Zhang L, Sun J, et al. Construction and validation of a nomogram to predict overall survival in patients with breast sarcoma. Front Oncol. 2022;12:899018. Epub 2022/10/25.. PubMed PMID: 36276138; PubMed Central PMCID: PMCPMC9582126. https://doi.org/10.3389/fonc.2022.899018
  25. Lim SZ, Ong KW, Tan BK, Selvarajan S, Tan PH. Sarcoma of the breast: an update on a rare entity. J Clin Pathol. 2016;69(5):373-81. Epub 2016/01/06. PubMed PMID: 26729013. https://doi.org/10.1136/jclinpath-2015-203545
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.